Astrid M. van Huizen
A5090375728- Autoimmune Bullous Skin Diseases
- Pharmaceutical studies and practices
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Nail Diseases and Treatments
- Patient-Provider Communication in Healthcare
- Allergic Rhinitis and Sensitization
- Health Systems, Economic Evaluations, Quality of Life
- Empathy and Medical Education
- Monoclonal and Polyclonal Antibodies Research
- Food Allergy and Anaphylaxis Research
- Mental Health and Psychiatry
- Environmental Conservation and Management
- Asthma and respiratory diseases
- Autoimmune and Inflammatory Disorders Research
- Biosimilars and Bioanalytical Methods
- Vascular Tumors and Angiosarcomas
- Palliative Care and End-of-Life Issues
- COVID-19 Clinical Research Studies
- Cardiac tumors and thrombi
- Rheumatoid Arthritis Research and Therapies
- COVID-19 and healthcare impacts
- Vascular Malformations and Hemangiomas
- Dutch Social and Cultural Studies
- Microscopic Colitis
Amsterdam University Medical Centers
2020-2025
Public Health Service of Amsterdam
2023-2024
University of Amsterdam
2020-2024
Oxfam
2023
Liechtenstein Institute
2023
John Wiley & Sons (United States)
2023
Hudson Institute
2023
John Wiley & Sons (United Kingdom)
2023
Recently, a distinct subgroup of vascular neoplasms has been identified, characterized by NFATC-related fusions. Although existing literature is limited, these lesions histologically show variable appearance with tendency for local recurrence but not distant spread. Therefore, they likely fall within the "benign" or at most in "local aggressive"/"borderline" tumor category according to International Society Study Vascular Anomalies (ISSVA) classification scheme. Up now, tumors fusions have...
Importance A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because affordable globally available, uniform could potentially optimize the treatment of patients with worldwide. Objective To reach international consensus among experts on adult pediatric identify potential future research topics. Design, Setting, Participants Between September 2020 March 2021, survey study modified eDelphi procedure that was developed distributed by...
Anti-drug antibodies (ADA) are formed in patients treated with adalimumab (ADL). This might increase clearance of ADL, potentially causing a (secondary) non-response. Combination therapy ADL and methotrexate (MTX) reduces ADA levels has clinical benefit rheumatologic diseases. In psoriasis however, the long-term effectiveness safety have not been studied.To investigate three-year follow-up data combined MTX compared to monotherapy ADL-naive moderate severe plaque type psoriasis.We conducted...
Abstract Background Despite the widespread off‐label use of methotrexate (MTX) for treatment atopic dermatitis (AD), there is limited high‐quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding strategies. Objective The aim this study was to achieve international consensus among AD experts standardize regimen MTX in adults children with AD. Methods An electronic Delphi (eDelphi) conducted from October 2021 September 2022. Recruitment...
Previously, we showed that the combination of methotrexate and adalimumab treatment leads to less antidrug antibody development. In this study, quantify pharmacokinetics/pharmacodynamics (PK/PD) evaluate influence cotreatment. A population PK-PD model was developed using prospective data from 59 patients with psoriasis (baseline PASI = 12.6) receiving over 49 weeks. Typical PK PD parameters their corresponding interpatient variability were estimated. We performed a covariate analysis assess...